The Corporate Forum is delighted to introduce Verastem, Inc. to an audience of Boston retail investors.
Located in Cambridge, MA, Verastem is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells along with companion diagnostics.
The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. The company is listed on NASDAQ with sufficient capital to late 2015/early 2016 with a potential registration study slated for midyear 2013.
The company is backed by research from the Whitehead and Broad Institutes of MIT and Harvard. Scientific cofounder and chair of the scientific advisory board, Robert Weinberg, PhD, is widely considered the father of the genetic basis of cancer.
The management team includes Chairman/CEO Christoph Westphal, MD, PhD, (founder/CEO of VSTM, SIRT, MNTA, ALNY), COO Robert Forrester, and Lead Director Henri Termeer (former Genzyme Chairman/CEO.)